What does this video actually claim?
Ivan Birkas claims most men over 40 have low IGF-1 levels (around 120 when they should be 250), causing stubborn fat, poor recovery, low testosterone, and bad lipid profiles. He suggests testing IGF-1 as a proxy for growth hormone and offers to guide followers through using ipamorelin and CJC-1295 peptides.
The post positions IGF-1 testing as a single diagnostic solution for multiple metabolic issues. It promises a straightforward protocol using growth hormone-releasing peptides to address these problems based on lab results.
Are the IGF-1 claims accurate?
The numbers Birkas cites don't match established reference ranges. Most labs use age-adjusted IGF-1 ranges, with men 40-50 typically ranging from 101-267 ng/mL, not a universal target of 250.
The NHANES III study (Brabant et al., Clinical Endocrinology, 2003) found IGF-1 naturally declines with age, dropping about 14% per decade after age 30. A 45-year-old man with IGF-1 of 120 ng/mL might be completely normal, not deficient.
While IGF-1 does correlate with growth hormone output, it's influenced by nutrition, liver function, and other factors. The American Association of Clinical Endocrinologists doesn't recommend routine IGF-1 testing in healthy adults without specific symptoms of growth hormone disorders.
Do these peptides actually work?
Both ipamorelin and CJC-1295 can increase growth hormone release, but the clinical evidence for body composition benefits is limited. A 2015 study (Sigalos et al., Maturitas) found CJC-1295 increased GH and IGF-1 levels but didn't measure body fat or muscle mass changes.
The most strong data comes from actual growth hormone therapy, not peptides. The GH-2000 study (Johannsson et al., Journal of Clinical Endocrinology, 2009) found growth hormone replacement in deficient adults improved body composition but required careful monitoring for side effects like joint pain and insulin resistance.
Birkas oversells the connection between low IGF-1 and testosterone. While growth hormone and testosterone pathways interact, treating one doesn't automatically fix the other.
What are the actual risks here?
The FDA hasn't approved ipamorelin or CJC-1295 for anti-aging or body composition purposes. Most peptide clinics operate in a regulatory gray area, selling these compounds as research chemicals.
Growth hormone stimulation can worsen insulin resistance and increase diabetes risk. A 2019 meta-analysis (Liu et al., Cochrane Database) found growth hormone therapy in non-deficient adults caused more side effects than benefits.
Birkas offers to guide peptide protocols through DMs, which bypasses proper medical oversight. These compounds need monitoring for glucose levels, joint symptoms, and potential tumor growth if someone has undiagnosed cancer.
What should you actually know?
IGF-1 testing makes sense if you have specific symptoms of growth hormone deficiency: severe fatigue, muscle weakness, or documented pituitary problems. It's not a routine screening test for feeling tired at 45.
The symptoms Birkas attributes to low IGF-1 (stubborn fat, poor recovery, low testosterone) have many causes. Sleep disorders, insulin resistance, and hypogonadism all need specific evaluation and treatment.
If you're genuinely concerned about growth hormone deficiency, see an endocrinologist. They'll do proper stimulation testing beyond just IGF-1 levels and can prescribe FDA-approved growth hormone if you actually need it.